Eurofins Viracor said on Thursday that it has acquired an exclusive license to a sequencing-based liquid biopsy technology developed at Cornell University for tracking tissue damage in COVID-19 and transplant patients.

Cue Health said on Wednesday that it has received interim order authorization from Health Canada to sell its at-home molecular COVID-19 self-test in that country.

DiaSorin on Wednesday said that its 2021 revenues rose 41 percent year over year.

On March 16, PHASE Scientific’s INDICAID COVID-19 Rapid Antigen At-Home Test get EUA issued by the US FDA.

Jilin Province has ordered 12 million antigen detection reagents nationwide in a short period of time, some have been delivered.

Lucira Health on Thursday reported a huge year-over-year surge in revenues for the fourth quarter of 2021 on ramped-up manufacture and sale of the company's molecular at-home COVID-19 tests.

A review of adverse events following vaccination against COVID-19 with mRNA vaccines in the USA confirms that most side effects were mild and decreased substantially after one day.

A new viral transport medium that enables collection and rapid inactivation of the SARS-CoV-2 virus, and stabilizes viral RNA at ambient temperature for transportation and use in in vitro diagnostic testing procedures, is now available in Europe.

Moderna and Thermo Fisher Scientific Inc.announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the U.S. of Spikevax®, Moderna’s COVID-19 vaccine, and other investigational mRNA medicines in its pipeline.

According to Radio Television Hong Kong and Sing Tao Daily reports on February 20, a study found that the new coronavirus may cause hypogonadism and decreased fertility in male patients, and patients will still be affected after recovery.